Podcasts about AML

Host Charlie Beetson speaks with Henning Varner (Chief Risk Officer, SEB), Carl-Simon (Senior Risk Manager, Juni), and Dushyanthi Joachim (Global Process Manager - Transactions Monitoring, SEB) in a discussion focused on anti-money laundering, regulation, and risk oversight in the financial industry. Together, they delve into how Nordic institutions are addressing regulatory requirements, refining transaction monitoring processes, and enhancing financial crime controls. This episode offers insights into AML frameworks, compliance strategies, and the evolving landscape of risk management within financial services.

Think about the road you took to work, the flight you booked for your next holiday, or even the property you're looking to buy. What if they were all made possible by shadowy deals between powerful corporations and oligarchs?But surely this couldn't be happening in Scandinavia, where trust and transparency are so important…could it?Our expert hosts, Fredrik Riiser and Robin Lycka, team up to reveal: how oligarchs embedded themselves across ScandinaviaThe pair discuss: the businesses with hidden ownership secrets, how it happens, and what can be done about it.Producer: Matthew Dunne-MilesEditor: Dominic DelargyEngineer: Nicholas ThonSubscribe to our newsletter, Fresh Laundry, here.Be part of our summer podcast series, The Soapbox, here.Producer: Matthew Dunne-MilesEditor: Dominic DelargyEngineer: Nicholas Thon____________________________________The Laundry podcast explores the complex world of financial crime, anti-money laundering (AML), compliance, sanctions, and global financial regulation.Hosted by Marit Rødevand, Fredrik Riiser, and Robin Lycka, each episode features in-depth conversations with leading experts from banking, fintech, regulatory bodies, and investigative journalism.Tune in as we dissect headline news, unpack regulatory trends, and examine the real-world consequences of non-compliance — all through a uniquely compliance-focused lens.The Laundry is proudly produced by Strise.Get in touch at: laundry@strise.ai Hosted on Acast. See acast.com/privacy for more information.

In this episode of the Oyster Stew podcast, Oyster Consulting's Ed Wegener and Bryan Jacobsen break down how firms can implement risk-based monitoring, tailor training for frontline roles, conduct effective investigations, and ensure your firm's Suspicious Activity Report (SAR) filings are what regulators require.Key Takeaways What regulators expect from your AML compliance programRisk-based surveillance: Going beyond cookie-cutter monitoringHow to tailor red flag training by employee roleInvestigating suspicious activity: When to file a SAR, how to do it rightLeveraging third-party vendors for transaction surveillance and case managementCommon mistakes firms make—and how to avoid themOyster Consulting has the expertise, experience and licensed professionals you need, all under one roof. Follow us on LinkedIn to take advantage of our industry insights or subscribe to our monthly newsletter. Does your firm need help now? Contact us today!

In this episode, Cheryl Chapman, Annuities Specialist with 19 years of experience, joins Sherry Kelson, Director of the Life Team at The Brokerage Inc., to break down what agents need to know about annuities. Cheryl walks through the key requirements for selling annuities, including: A life and health license State-specific certifications Anti-money laundering (AML) training Errors & omissions (E&O) coverage Product-specific training She explains the main types of annuities—fixed, indexed, and single premium income annuities (SPIAs)—and shares how each can serve clients' long-term goals like retirement, college funding, or guaranteed income. With current interest rates around 5.3%, annuities are becoming an attractive, low-risk option offering tax-deferred growth and portfolio diversification. Cheryl also notes that annuities typically issue within a week, and agents can reach out to her directly for guidance and support. You can reach Cheryl through The Brokerage Inc. website. Learn more about partnering with The Brokerage Inc. by visiting our website, www.thebrokerageinc.com. Remember to like, share, and subscribe to our show!  New episodes are available every Tuesday. Join our Community! LinkedIn: https://www.linkedin.com/company/the-brokerage-inc-/   Facebook:  https://www.facebook.com/thebrokerageinc/  Instagram:  https://www.instagram.com/thebrokerageinc/  YouTube:  https://www.youtube.com/@TheBrokerageIncTexas  Website:  https://thebrokerageinc.com/ 

In today's episode of iGaming Daily, sponsored by Optimove, Ted Orme-Claye, Viktor Kayed, and Ted Menmuir break down the recent removal of Gibraltar and the UAE from the EU's Anti-Money Laundering (AML) watch list. Viktor, who originally broke the story for SBC News, details why this delisting marks a crucial turning point for these markets. Gibraltar, long regarded as a premier hub for European gaming operators and B2B technology providers, has worked swiftly to address shortcomings flagged by the Financial Action Task Force (FATF)—strengthening its AML controls, asset seizure processes, and gambling oversight to restore its market reputation and access to EU business channels.The discussion then shifts to the United Arab Emirates, a fast-emerging player in the global iGaming scene. The UAE's removal from the AML list follows its creation of the General Commercial Gaming Regulatory Authority (GCGRA), a step towards a legalised and regulated gaming environment in the region. With Wynn Resorts' Ras Al Khaimah project on the horizon, the UAE is positioning itself not just as a potential destination for high-end land-based gaming but also as a future hub for game development, technology platforms, and iGaming investment—serving as a bridge to key Asian markets. However, the three caution against overestimating its immediate impact on broader online gambling in Asia, pointing to the unique complexities of neighboring countries such as China, India, and Japan.This episode highlights why these regulatory shifts are a game-changer for investors, gaming operators, and tech innovators alike. The removal from the EU and FATF “gray lists” reduces financial risk, removes regulatory barriers, and sends a strong signal of market credibility—opening doors for partnerships, funding, and new ventures in both Gibraltar and the UAE. Host: Ted Orme-ClayeGuests: Ted Menmuir & Viktor KayedProducer: Anaya McDonaldEditor: James RossiGaming Daily is also now on TikTok. Make sure to follow us at iGaming Daily Podcast (@igaming_daily_podcast) | TikTok for bite-size clips from your favourite podcast. Finally, remember to check out Optimove at https://hubs.la/Q02gLC5L0 or go to Optimove.com/sbc to get your first month free when buying the industry's leading customer-loyalty service.

The latest episode of the Gaming News Canada Show is one of the two-part type as we pack our suitcase and fill up the GNC vehicle before heading to the city below Uxbridge for this week's Canadian Gaming Summit. Canadian Gaming Association senior executive Amanda Brewer returned to the show for a rapid round on what's happening across the national gaming industry these days. That includes the slow road to an open market in Alberta, the wait at iGaming Ontario for a new boss and the launch of a centralized self-exclusion program, and lobbying efforts for open gambling regimes in British Columbia. We also had a chat about this week's summit, where Brewer will moderate “The urgent need to modernize Canada's AML framework” panel Wednesday a.m. with Derek Ramm (Kinectify), Brian Terranova (FanDuel) and Heinen Hutchison Robitaille LLP partner Scott Hutchison. Craig Cornforth of EPIC Global Solutions took time out from the SBC Summit Malta last week to make his maiden GNCS appearance. The former auto dealer told his poignant story around gambling addiction and the road to recovery that led him to join EPIC and its work in the prevention of gambling harm. Cornforth will be on stage with Alistair Facciol (Rhino Entertainment), Ryan McCarthy (BCLC), Covers journalist Geoff Zochodne and yours truly for a Thursday morning chin wag on “Regulation and responsibility: how the new politics affect player protection”. Hosted on Acast. See acast.com/privacy for more information.

Stephan & Matt discuss the ‘Save Our Wallets' campaign, which aims to protect non-custodial wallets from regulatory challenges posed by the U.S. government. He highlights the legal risks developers face due to broad interpretations of regulations and the potential consequences of future administrations. The importance of advocacy for legislative change, user engagement, and improving user experience in Bitcoin transactions are emphasized. Additionally, the conversation touches on the implications of AML and FATF regulations, the evolution of wallet technologies, and the need for research into Miner Extractable Value (MEV) in Bitcoin. They also discuss various aspects of Bitcoin and Ethereum, focusing on the implications of MEV (Miner Extractable Value), the risks of mining centralization, and the importance of investing in solutions rather than relying on consensus changes. They explore the challenges posed by private order flow, the philosophical differences in Bitcoin development, and the future of Bitcoin Core and node adoption.Takeaways

Lyudmyla Kozlovska, President, Open Dialogue Foundation discusses the intersection of Bitcoin, human rights, and the weaponization of financial regulations. She highlights the dangers of transnational financial repression, where authoritarian regimes exploit financial action task force (FATF) and anti-money laundering (AML) regulations to target individuals and organizations. The discussion emphasizes the need for privacy protection, legislative change, and active advocacy to safeguard civil liberties in the face of increasing surveillance and repression.Takeaways

Episode 367: Pharmacology 101: PARP Inhibitors “We know that in cells that are proliferating very quickly, including cancer cells, single-strand DNA breaks are very common. When that happens, these breaks are often repaired by the PARP enzyme, and the cells can continue their replication process. If we block PARP, that repair cannot happen. So in blocking that, these single-strand breaks then lead to double-strand breaks, which ultimately is leading to cell apoptosis,” Danielle Roman, PharmD, BCOP, manager of clinical pharmacy services at the Allegheny Health Network Cancer Institute in Pittsburgh, PA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the PARP inhibitor drug class. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by June 13, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the use of PARP inhibitors in cancer care. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series Episode 330: Stay Up to Date on Safe Handling of Hazardous Drugs Episode 232: Managing Fatigue During PARP Inhibitor Maintenance Therapy Episode 227: Biomarker Testing, PARP Inhibitors, and Oral Adherence During Ovarian Cancer Maintenance Therapy ONS Voice articles: PARP Inhibitors and Ovarian Cancer Genomics May Trick PARP Inhibitors to Treat More Cancers Oncology Drug Reference Sheet: Niraparib ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) Safe Handling of Hazardous Drugs (fourth edition) ONS courses: Safe Handling Basics Clinical Journal of Oncology Nursing articles: PARP Inhibition: Genomics-Informed Care for Patients With Malignancies Driven by BRCA1/BRCA2 Pathogenic Variants Talazoparib Plus Enzalutamide in Patients With HRR-Deficient mCRPC: Practical Implementation Steps for Oncology Nurses and Advanced Practice Providers Oncology Nursing Forum article: Familiarity and Perceptions of Ovarian Cancer Biomarker Testing and Targeted Therapy: A Survey of Oncology Nurses in the United States Oral Anticancer Medication Care Compass: Resources for Interprofessional Navigation ONS Biomarker Database ONS Oral Anticancer Medication Learning Library ONS Oral Anticancer Medication Toolkit Oral Chemotherapy Education Sheets To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “The big toxicities here to watch for are primarily hematologic toxicities. It is one of those targeted therapies that does affect blood cell counts. So I'd say the blood cell count that is most commonly affected here is the hemoglobin. So, anemia very frequent complication that we see, probably a little bit more with olaparib compared with other drugs, but we see it as a class side effect. And we can also see neutropenia and thrombocytopenia with these agents, probably a little bit more with niraparib versus the others, but again, you can see it across all of these drugs.” TS 8:16 “We mentioned that rare risk of MDS and AML. This isn't a particularly scary thing if you talk to patients about it. Because of the rarity that we see this, it isn't something that we need to overemphasize, but I think careful monitoring of blood counts in is stressing the importance of that and early intervention here is very important.” TS 16:55 “This is a collaborative effort. And because of the home administration here, these patients do need to be followed very closely. So we are not laying eyes on them usually with the frequency that we do when we have patients actually coming into our infusion centers for treatments—so making sure that there is a plan for regular follow-up with these patients to ensure that they're getting that lab work done, that that's being looked at closely, that we're adjusting the dose if we need to based on that lab work, that we are managing the patient's fatigue. Again, that potentially dose reductions may be needed if patients are having that extreme fatigue.” TS 19:34 “I think one of those [misconceptions] could be that they're only effective in patients that have that BRCA1/2 mutation. And again, remember here that there is some data in particular disease states that we can use them and that they work in the absence of those mutations.” TS 25:12

In today's episode, we spoke with Naval Daver, MD, about the evolving role of menin inhibition in acute myeloid leukemia (AML) and emerging data with revumenib (Revuforj) presented across ongoing clinical trials. Dr Daver is a professor in the Department of Leukemia and director of the Leukemia Research Alliance Program at The University of Texas MD Anderson Cancer Center in Houston, Texas.

Uma Borate, MBBS, MS, The Ohio State University, Cleveland, OH Recorded on May 27, 2025 Uma Borate, MBBS, MS Associate Professor, Division of Hematology Acute Leukemia Clinical Research Disease Group Leader The Ohio State University Cleveland, OH What's changing in acute myeloid leukemia (AML)? Join Dr. Uma Borate from The Ohio State University in Columbus, Ohio, as she dives into emerging breakthroughs in AML biology, including molecular drivers, menin inhibitors, and the challenges of developing bispecifics and CAR T-cell therapies. She also shares updates from the LLS Beat AML® Master Clinical Trial and ongoing clinical trials, and reflects on the evolving treatment landscape across age groups. Don't miss this dynamic conversation packed with expertise and hope for the future of AML!

The Laundry was recently the closing act at Finland's biggest event for the AML industry – after a day of talks from expert speakers across banking, fintech, payments, consultancy, law enforcement, and academia. After soaking up all the valuable information like sponges – our panel are bringing some of the biggest, best, and brightest takes to you!Our expert host, Marit Rødevand, is joined by Christian Elkjær, Senior Manager of Third Party Risk & Compliance Advisory at Dun & Bradstreet, and Juuso Paulasuo, Business Development Manager at SOK, to reveal: what you can learn about the future of AML from Helsinki. The panel discuss: the changing face of regulation, the emerging risks in AML and CTF, and the practical steps banks should be taking on AI and compliance culture.Subscribe to our newsletter, Fresh Laundry, here.Be part of our summer podcast series, The Soapbox, here.Producer: Matthew Dunne-MilesEditor: Dominic DelargyEngineer: Nicholas Thon____________________________________The Laundry podcast explores the complex world of financial crime, anti-money laundering (AML), compliance, sanctions, and global financial regulation.Hosted by Marit Rødevand, Fredrik Riiser, and Robin Lycka, each episode features in-depth conversations with leading experts from banking, fintech, regulatory bodies, and investigative journalism.Tune in as we dissect headline news, unpack regulatory trends, and examine the real-world consequences of non-compliance — all through a uniquely compliance-focused lens.The Laundry is proudly produced by Strise.Get in touch at: laundry@strise.ai Hosted on Acast. See acast.com/privacy for more information.

In this second of a two-part series, Nick Lewis, Managing Director for the High Risk Client Unit at Standard Chartered Bank, returns to the AI in Business podcast to unpack the ongoing transformation of anti-financial crime efforts in an increasingly digitized world. In this episode, Nick and Emerj Editorial Director Matthew DeMello examine the persistent tension between rule-based alert systems and the nuanced, judgment-driven work of human investigators in financial crime prevention. Nick highlights how current AML workflows still rely heavily on deterministic systems that struggle to distinguish legitimate anomalies from criminal behavior—and why AI solutions must be deployed carefully to avoid removing critical human oversight. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business' podcast! If you've enjoyed or benefited from some of the insights of this episode, consider leaving us a five-star review on Apple Podcasts, and let us know what you learned, found helpful, or liked most about this show!

Welcome to the Daily Compliance News. Each day, Tom Fox, the Voice of Compliance, brings you compliance-related stories to start your day. Sit back, enjoy a cup of morning coffee, and listen in to the Daily Compliance News. All from the Compliance Podcast Network. Each day, we consider four stories from the business world: compliance, ethics, risk management, leadership, and general interest, all relevant to the compliance professional. Top stories include: Russian crypto charged with AML and sanctions violations. (FT) Trump Administration killing off border businesses with regulations. (NYT) Google takes a big gamble and goes to trial. (Reuters) FINRA defeats legal challenge. (Forbes) Learn more about your ad choices. Visit megaphone.fm/adchoices

The Canadian Gaming Association has been active for quite some time now in advocating for updates to anti-money laundering laws in our home and native land with the expansion of legal gambling. Dave Briggs addressed the topic at the beginning of the year with CGA boss Paul Burns, who said the uncertain political climate at that time most likely meant no movement until this fall. The CGA established a committee to continue moving ahead with its efforts to update the AML rules and regulations. The chair of that committee, Derek Ramm, was our guest on a new episode of the Gaming News Canada Show. Ramm, the Global Head of Advisory Services for Kinectify, knows AML like Corey Perry knows how to torment opponents, with a resume that includes stops with Canada's financial intelligence unit (FINTRAC), the Alcohol and Gaming Commission of Ontario, the Ontario Lottery & Gaming Corporation (OLG), and the Bermuda Casino Gaming Commission. He will appear on “The urgent need to modernize Ontario's AML framework” panel with moderator Amanda Brewer, FanDuel's Brian Terranova and Scott Hutchison of Heinen Hutchison Robitaille LLC at next week's Canadian Gaming Summit in the city below Aurora. Along with discussing Kinectify's role in identifying suspicious activity and working with stakeholders in Canada and the U.S., Ramm also answered our questions about the problems for operators in Ontario's open market when it comes to AML. That included a hacking escapade in 2024 that made it impossible for operators to file suspicious transaction reports to FINTRAC, and hiccups by iGaming Ontario on data collection and technology since the opening of the market in April 2022. Hosted on Acast. See acast.com/privacy for more information.

Hello, and welcome to episode 160 of the Financial Crime Weekly Podcast, I'm Chris Kirkbride. In this week's episode, we look at fresh developments in sanctions enforcement, money laundering crackdowns, and fraud investigations. The UK government is pressuring Roman Abramovich over £2.5 billion in frozen funds from Chelsea FC's sale, while OFAC targets Guyanese and Colombian drug traffickers using narco-subs and secret airstrips. We explore how Suspicious Activity Reports (SARs) are strengthening financial crime investigations and discuss the European Commission's push to grey-list Monaco over lingering AML deficiencies. Plus, AUSTRAC warns of AI-driven money laundering risks, and the EPPO takes down a €100 million VAT fraud network.A transcript of this podcast, with links to the stories, will be available by Monday at www.crimes.financial.

"We need to get the law changed so that developers, so that people running these kinds of wallets are protected so that we can have access to these things in the U.S." In this episode of THE Bitcoin Podcast, Walker America talks with Bitcoin developer Matt Corallo about the Blockchain Regulatory Certainty Act (BRCA), why BRCA matters for wallet development and access in America, non-custodial wallets, Spiral, Vibe coding wallets, Bitcoin mining and mining pool centralization, the Lightning Network and other Layer 2s, Sats vs Bits vs Bitcoin, other ongoing debates in the Bitcoin community. CALL YOUR REPS: https://saveourwallets.org/ Follow Matt: X: https://x.com/TheBlueMatt Nostr: https://primal.net/mattcorallo THE Bitcoin Podcast Partners: > GET FOLD: https://use.foldapp.com/r/WALKER > SIGN UP FOR THE FOLD BITCOIN REWARDS CREDIT CARD: https://foldapp.com/credit-card?r=UZoiP > Get the BITKIT mobile wallet: https://get.bitkit.to/walker > http://bitbox.swiss/walker -- use promo code WALKER for 5% off the Bitcoin-only Bitbox02 hardware wallet. Summary: Matt from Spiral discusses the importance of the Blockchain Regulatory Certainty Act, which aims to clarify regulations around non-custodial wallets and protect developers from being classified as money transmitters. The act, introduced by Representatives Emmer and Torres, seeks to amend the law so that developers of non-custodial platforms are not subject to KYC and AML requirements. Matt emphasizes the need for the Bitcoin community to pressure Congress to pass the act to prevent potential restrictions on access to innovative wallet technologies in the US. ***** If you enjoy THE Bitcoin Podcast you can help support the show by doing the following: FOLLOW ME (Walker) on @WalkerAmerica on X | @TitcoinPodcast on X | Nostr Personal (walker) | Nostr Podcast (Titcoin) | Instagram

There is a new look to The Bookkeepers' Podcast as Jo and Zoe share their real life stories to tackle a common challenge many aspiring bookkeepers face: how to start a virtual bookkeeping practice from home—particularly after facing redundancy. Drawing from their own experience and real-life questions from their Facebook community, Jo and Zoe walk through the essential steps needed to set up a compliant, confident and client-ready bookkeeping business. From choosing your business structure and securing AML supervision to creating engagement letters and setting prices, this episode is packed with foundational advice for new and returning practice owners. Jo shares her personal story of being made redundant and how that pivotal moment led to building a practice that aligned with her lifestyle and values. Zoe explores the mindset shifts required to move from an employee mentality to business owner confidence, especially when it comes to pricing and valuing your expertise. The conversation also unpacks the pitfalls of hourly pricing, the emotional impact of redundancy, and the need to invest in yourself and your business. Whether you're at the beginning of your journey or considering a refresh, this episode will help you lay the right foundations. You Will Learn: Why redundancy can be a powerful catalyst for starting your own practice. The essential legal and regulatory steps to set up a bookkeeping business. The mindset shift from employee to business owner. Why pricing by the hour is outdated—and what to do instead. How to build confidence, even when you're feeling uncertain. The importance of identifying your ideal client early on. 00:00 - Intro: How to Start a Virtual Bookkeeping Practice 00:17 - Starting a Business After Redundancy 07:29 - Step-by-Step: Setting Up a Bookkeeping Business 12:04 - Do You Need a Solicitor for Contracts? 14:01 - Ideal Clients and Choosing Your Services 15:54 - Pricing Lessons from Bridesmaids' Dress Alterations 18:59 - The True Value of Your Time at Work 22:49 - What's the Minimum You Should Charge as a Bookkeeper? 26:07 - Why Hourly Rates Hold You Back ----------------------------------------------- About us We're Jo and Zoe and we help bookkeepers find clients, make more money and build profitable businesses they love. Find out about working with us in The Bookkeepers' Collective, at: 6figurebookkeeper.com/collective ----------------------------------------------- About our Sponsor This episode of The Bookkeepers' Podcast is sponsored by Xero. Get 90% off your first 6 months by visiting: https://xero5440.partnerlinks.io/6figurebookkeeper ----------------------------------------------- Promotion This video contains paid promotion. ----------------------------------------------- Disclaimer The information contained in The Bookkeepers' Podcast is provided for information purposes only. The contents of The Bookkeepers' Podcast is not intended to amount to advice and you should not rely on any of the contents of the Bookkeepers' Podcast. Professional advice should be obtained before taking or refraining from taking any action as a result of the contents of the Bookkeepers' Podcast. The 6 Figure Bookkeeper Ltd disclaims all liability and responsibility arising from any reliance placed on any of the contents of the Bookkeepers' Podcast.

Hot coral cards, instant money transfers, sleek onboarding, and mega funding rounds. Take yourself back to the 2010s and the fintech hype train was in full effect!Now the industry has grown up and handles more of our money than ever before – the pendulum is shifting on these ‘disruptors' who now face much of the same pressures as the big boys of banking.So, does fintech continue to exist if their risk appetite shrinks? Our expert host, Marit Rødevand, is joined by Craig McLeod, Head of UK Financial Crime Compliance, FTI Consulting to reveal: how fintech grows up and gets compliant!The pair discuss: the perception of compliance in fintech's global rise, how fintechs and payments providers balance compliance with innovation, and what happens to the future of fintech and payments as the fines comes raining down! Subscribe to our newsletter, Fresh Laundry, here.Be part of our summer podcast series, The Soapbox, here.Producer: Matthew Dunne-MilesEditor: Dominic DelargyEngineer: Nicholas Thon____________________________________The Laundry podcast explores the complex world of financial crime, anti-money laundering (AML), compliance, sanctions, and global financial regulation.Hosted by Marit Rødevand, Fredrik Riiser, and Robin Lycka, each episode features in-depth conversations with leading experts from banking, fintech, regulatory bodies, and investigative journalism.Tune in as we dissect headline news, unpack regulatory trends, and examine the real-world consequences of non-compliance — all through a uniquely compliance-focused lens.The Laundry is proudly produced by Strise.Get in touch at: laundry@strise.ai Hosted on Acast. See acast.com/privacy for more information.

What does a lifetime of championing Mormon arts look like? In this special episode of Dialogue Out Loud, we honor Glen Nelson, recipient of the 2025 Lifetime Achievement Award from the Association for Mormon Letters.… The post AML 2025 Lifetime Achievement Award Winner Glen Nelson appeared first on Dialogue Journal.

In this episode, Ari Redbord, TRM's Global head of Policy, sits down with Kate Eyerman, Chief Compliance Officer at Blockchain.com, to unpack her unconventional path from the US State Department and Treasury to leading compliance in one of crypto's most dynamic environments.With deep experience in counter-terrorism financing and sanctions policy, Kate brings a policy-informed lens to navigating the evolving risks in the digital asset space.Kate and Ari explore the practical challenges of applying legacy financial compliance standards — like the Travel Rule — to blockchain-based finance, and how a strong foundation of AML and sanctions controls enables innovation. Kate also shares candid reflections on the shift from policy theory to operational reality and why public-private partnerships are more than buzzwords in today's crypto compliance landscape.From developing transaction monitoring protocols to evaluating emerging threats like AI-generated fraud, the emerging impact on AI on compliance and KYC, Kate emphasizes a risk-based approach rooted in mission-driven strategy. She also discusses the importance of educating policymakers, engaging with global regulators, and maintaining an agile compliance posture amid fast-moving technologies.And outside of compliance? Kate takes a risk-based approach to kayaking whitewater rivers — an apt metaphor for navigating crypto compliance in 2025.

What does a lifetime of championing Mormon arts look like? In this special episode of Dialogue Out Loud, we honor Glen Nelson, recipient of the 2025 Lifetime Achievement Award from the Association for Mormon Letters.… The post AML 2025 Lifetime Achievement Award Winner Glen Nelson appeared first on Dialogue Journal.

In this episode of Money Tales, our guest is Sophie Bertin. You know that feeling when everything looks good on paper, a great job, supportive colleagues, a solid paycheck, but something inside keeps whispering, this isn't it! That was Sophie. She had a comfortable life, but comfort wasn't enough. It took a spark - an unexpected stat about entrepreneurs from a business school dean when Sophie was at a less-than-satisfying moment in her career - for her to realize: “Why am I in the 50% who haven't taken the leap?” That catalyzed her turning point. Sophie Bertin has a varied career path, from strategic consultancy, to banking operations, to the European Commission and now turned entrepreneur. She recently founded Serapy with the aim of improving corporate compliance training through the combination of simulations, gamification, role play and online tools. Serapy uses the latest educational theories to provide trainings with increased retention rate, and combines that with AI tools to enhance the learning process. Serapy is currently present in Switzerland, Bulgaria, Portugal, France and the UAE. Serapy has been accepted in the incubation program of the Unicorn Factory Lisbon and of Station F in Paris. In addition to Serapy, Sophie has her own consultancy (Parnima Consulting) since 2016, where she works with top legal and regulatory firms, consultancy firms and financial clients on EU Regulations in the area of Financial Services, Foreign Subsidies and State Aid. She also serves as independent board member of Eastnets, a leading provider of AML, SWIFT and payments solutions. She sits on the Remuneration, Nomination and Governance Committee. Before becoming entrepreneur, Sophie was Group Head of Corporate Development and Managing Director of SIX Group (in Switzerland), in charge of strategy development, innovation and regulatory affairs. During the Financial Crisis, she served as Head of Unit at the Directorate General for Competition within the European Commission. There, she was responsible for the review and approval of the State aid provided by Member States to the financial services (mostly banks) during the financial crisis of 2008-2014. Prior to her role with the European Commission, Sophie held senior positions within SWIFT, where she was globally in charge of Asset Servicing; with The Bank of New York Mellon; and worked with the top consultancies McKinsey and later Bain &Co. She started her career path as IT and database programmer, which is very helpful now with the latest AI tools she uses in her start-up. She started her studies in Vienna, graduated from the Ecole Supérieure de Commerce de Paris, holds an MBA from INSEAD and a post-graduate diploma in EU Competition Law from King's College. She holds also a diploma from the Swiss Board Institute. She is member of the Executive Committee of the INSEAD Alumni organization, and she is also the founder and president of the global INSEAD Women in Business Club. Recently, she finished an advanced AI Mastery class and won the award for the best AI Application Builder. She is promoting and advocating for AI literacy among women and through the INSEAD Women in Business Club organizes events for Women in AI.

We talked to the mother of someone who has fought through AML, Anemia and a bone marrow transplant - Lisa Heiden shares the inspiring and heartbreaking story and the climbing back she has gone through since her 2020 diagnosis. Also this half we give away the ultimate Minnesota Twins broadcast package where you can go behind the scenes of the Twins broadcast - again, all courtesy of your donations to the Cure Blood Cancer Radio Auction alongside NMDP!

In this week's episode, we'll hear about new insights into PU.1-mutated agammaglobulinemia. Researchers show that haploinsufficiency of the master transcriptional regulator PU.1 causes agammaglobulinemia and dendritic cell deficiencies. These patients experience an array of infectious and non-infectious complications, but not leukemia. After that: venetoclax-based induction therapy in younger patients with AML. Venetoclax plus decitabine was associated with superior safety and non-inferior response rates compared to intensive chemotherapy. Is it time to consider lower-intensity therapy beyond older and unfit patients? Finally, a focus on venous thromboembolism. Researchers link BGAT, an enzyme pivotal to determining blood type, to risk of future VTE. They say high plasma levels of BGAT contribute to risk above and beyond what can be explained by von Willebrand factor and Factor VIII.Featured Articles:One hundred thirty-four germ line PU.1 variants and the agammaglobulinemic patients carrying themVenetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AMLHisto–blood group ABO system transferase plasma levels and risk of future venous thromboembolism: the HUNT study

It's been a wild ride for Syria's interim President, Ahmed al Sharaa.Recently, he was photographed alongside Donald Trump in Riyadh, marking a historic moment: the announcement of the end of U.S. sanctions on Syria. It's quite the turnaround for a man who once had a $10 million bounty on his head.There's a growing sense of optimism about Syria's reintegration into the global financial system, after years of international isolation.Our expert host, Marit Rødevand, is joined by Luma Zitani, financial crime practitioner, to ask: Trump lifts sanctions on Syria – now what? The pair discuss: how sanctions have impacted Syria for decades, the impact of Trump's announcement, and can you just turn off sanctions like turning off a tap?Subscribe to our newsletter, Fresh Laundry, here.Be part of our summer podcast series, The Soapbox, here.Producer: Matthew Dunne-MilesEditor: Dominic DelargyEngineer: Nicholas Thon____________________________________The Laundry podcast explores the complex world of financial crime, anti-money laundering (AML), compliance, sanctions, and global financial regulation.Hosted by Marit Rødevand, Fredrik Riiser, and Robin Lycka, each episode features in-depth conversations with leading experts from banking, fintech, regulatory bodies, and investigative journalism.Tune in as we dissect headline news, unpack regulatory trends, and examine the real-world consequences of non-compliance — all through a uniquely compliance-focused lens.The Laundry is proudly produced by Strise.Get in touch at: laundry@strise.ai Hosted on Acast. See acast.com/privacy for more information.

The Trump administration has suspended new visa applications for foreign students to give US embassies around the world more time to vet applicants and also prepare to carry out deeper checks on their social media history.Larry Donnelly, law lecturer at the University of Galway, and Chris Clifford, president of AMLÉ, the union of students in Ireland, join The Last Word to discuss this latest news and what it could mean for Irish students heading to the US. Catch the full chat by pressing the 'Play' button on this page!

Want more MTM Vegas? Check out our Patreon for access to our exclusive weekly aftershow! patreon.com/mtmvegas Episode Description This week Fontainebleau continued its run in the news as its President Maurice Wooden was able to secure his gaming license. During his hearing it leaked that Fontainebleau is possibly under investigation for violating AML policies. While the license is good news for the property, the revelation of an investigation leaves a murky future. In other news Paramount announced an immersive Top Gun Experience coming to Las Vegas in 2028. With simulators and the bar recreated from the movies, will it be successful on a plot of land near Strat? In other #news we discuss Circa's insane new Grandissimo contest, the failed Grandissimo casino, a closure coming to W Las Vegas, Caesars targeting Canadian customers, Flamingo's Go pool full of people, a new alien museum in Southern Nevada and what is good and bad about Fontainebleau's food hall. Episode Guide 0:00 Flamingo's Go Pool is FULL of people! 0:31 Circa's new insane “Grandissimo” football contest 2:36 Why does Circa host these no-rake football contests 3:18 Behind Jay Sarno's Grandissimo failed Vegas project 5:25 Why Circa's nods to Vegas history are a win 6:18 Caesars going after Canadian customers - 1:1? 7:42 Top Gun Experience coming to Las Vegas 8:58 Top Gun's bar could be a Vegas gamechanger 10:49 Knights Guard tryouts coming 12:25 Rivea closing at W Las Vegas (former Delano) 13:25 Fontainebleau's food court - A look at the value vs. quality 15:30 New alien museum open in Las Vegas area 16:35 Fontainebleau “under investigation” 18:35 Why are the newest Vegas casinos struggling with regulators?   Each week tens of thousands of people tune into our MtM Vegas news shows at http://www.YouTube.com/milestomemories. We do two news shows weekly on YouTube with this being the audio version. Never miss out on the latest happenings in and around Las Vegas! Enjoying the podcast? Please consider leaving us a positive review on your favorite podcast platform! You can also connect with us anytime at podcast@milestomemories.com.  You can subscribe on Apple Podcasts, Google Podcasts, Spotify or by searching "MtM Vegas" or "Miles to Memories" in your favorite podcast app. Don't forget to check out our travel/miles/points podcast as well!

An AML is seeking forgiveness from his girlfriend for asking her to remove a very specific tattoo!

An AML is seeking forgiveness from his girlfriend for asking her to remove a very specific tattoo!

Details, details, details, with today's HO and N-scale locomotive manufactures delivering engines with just about every detail you can imagine, we here at the old AML headquarters have discovered someone that's producing even more details for every facet of your layout, including locomotives and rolling stock. Chris Wallace is like almost everyone else in the hobby having been a model railroader for as long as he can remember but here's the twist, he's also a full-time 1:1 railroader that's discovered 3-D printers and a need for many details that haven't been available up till now. Whether it's trash cans, air conditioners, fire hydrants, tiedown chain, runaround hoses, or a whole host of details for specific locomotives Wallace Locomotives Works is your one stop shop. Tell ‘em Lionel sent you and see if that helps!!

David He, partner at Gunderson Dettmer sits down with Jeremy Au to dissect Southeast Asia's shifting startup and legal terrain. From the fallout of the eFishery scandal to the rise of ESG compliance and convertible notes, they explore how investor behavior and founder strategies are evolving. The discussion highlights governance gaps, tougher diligence, and why regional funding optimism may have stalled again. 07:12 E-Fishery Scandal as a Southeast Asian Theranos: David compares eFishery's collapse to Theranos—highlighting financial mismanagement, weak controls, and how one scandal can shake an entire region's credibility. 10:25 Due Diligence Now Takes Months, Not Weeks: Term sheets are no longer quick investors stretch due diligence timelines, run legal and commercial checks in parallel, and uncover more issues late in the process. 12:38 Surge in Use of Convertible Notes: Investors increasingly prefer convertible notes for their downside protection and maturity leverage, especially during uncertain market conditions. 19:15 ESG & Compliance Burden Rising for Founders: Startups now face investor-mandated ESG, AML, and governance standards originally meant for large institutions—often without the internal capacity to manage them. 24:32 Tariffs Trigger Global Uncertainty, Slow Exits: Trump-era tariffs hit Indonesia and Vietnam, affecting investor confidence and delaying IPOs and M&A despite startups themselves not being directly impacted. 27:11 Philippines Up, Indonesia Down: The Philippines is gaining momentum with underexposure and English fluency, while Indonesia cools down from overinvestment and post-eFishery fallout. 30:05 Down Rounds Are Less Stigmatized: Founders and investors alike are more open to valuation markdowns, with flexible deal terms helping break the deadlock in difficult fundraising climates. Watch, listen or read the full insight at https://www.bravesea.com/blog/david-he-scandal-shakes-trust Get transcripts, startup resources & community discussions at www.bravesea.com WhatsApp: https://whatsapp.com/channel/0029VakR55X6BIElUEvkN02e TikTok: https://www.tiktok.com/@jeremyau Instagram: https://www.instagram.com/jeremyauz Twitter: https://twitter.com/jeremyau LinkedIn: https://www.linkedin.com/company/bravesea English: Spotify | YouTube | Apple Podcasts Bahasa Indonesia: Spotify | YouTube | Apple Podcasts Chinese: Spotify | YouTube | Apple Podcasts Vietnamese: Spotify | YouTube | Apple Podcasts

In this episode of HemOnc Pulse, host Rahul Banerjee, MD, FACP of Fred Hutch Cancer Center is joined by myeloid malignancy expert Uma Borate, MBBS of The Ohio State University, for a high-impact discussion on one of hematology's hottest frontiers: early detection. As aggressive diseases like AML and MDS continue to outpace traditional diagnostics, this conversation dives into why spotting these cancers sooner isn't just helpful—it's lifesaving.  

In this episode of the Epigenetics Podcast, we talked with Ani Deshpande from Sanford Burnham Prebys about his work on epigenetic regulation and developing small molecules through high throughput screens for AML. Throughout our discussion, we delve into Dr. Despande's journey into the field of biology and science, tracing his evolution from a literature enthusiast in Mumbai to a dedicated cancer researcher. He reflects on his formative experiences during his PhD at Ludwig Maximilian University in Munich, where she developed murine models for refractory acute myeloid leukemia (AML). We examine these models' contributions to therapeutic discovery and understanding the intricate mechanisms underscoring AML's complexities. Transitioning to his postdoctoral work at Scott Armstrong's lab in Boston, Dr. Despande shares his insights on the importance of epigenetic regulators, such as DOT1L, in leukemias, and how they can serve as strategic therapeutic targets. His ambitious pursuit of translational research is further highlighted through his efforts in developing a conditional knockout mouse model and his collaborative work utilizing CRISPR technology to refine our understanding of epigenetic regulation in cancer pathogenesis. Moreover, we engage in a conversation about the challenges and opportunities that arise when establishing his lab at Sanford Burnham Prebys. Dr. Despande candidly discusses the delicate balance between pursuing topics of genuine interest versus adhering to grant fundability, underlining the tension researchers face in the current scientific landscape. His emphasis on the critical need for innovation within lab settings serves as a motivational call for emerging scientists to venture beyond the established templates that often inhibit groundbreaking discoveries. We conclude our dialogue with an exploration of his recent projects, which involve targeting specific epigenetic modifiers and how his lab's findings can contribute to greater understanding and potential treatments for not only AML but also other pediatric cancers driven by gene fusions. Dr. Despande's insights into the integration of modern technologies, such as CRISPR libraries, exemplify his commitment to pushing the boundaries of cancer research. In addition to discussing his scientific contributions, we touch upon Dr. Despande's foray into podcasting (The Discovery Dialogues), shedding light on his motivation to bridge the communication gap between scientists and the broader public. He articulates his desire to demystify scientific discoveries and promote awareness about the intricate journey of research that lays the groundwork for medical advancements. This multidimensional discussion not only highlights his scientific achievements but also emphasizes the importance of effective science communication in fostering public understanding and appreciation of research.   References Deshpande AJ, Cusan M, Rawat VP, Reuter H, Krause A, Pott C, Quintanilla-Martinez L, Kakadia P, Kuchenbauer F, Ahmed F, Delabesse E, Hahn M, Lichter P, Kneba M, Hiddemann W, Macintyre E, Mecucci C, Ludwig WD, Humphries RK, Bohlander SK, Feuring-Buske M, Buske C. Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10-positive leukemia. Cancer Cell. 2006 Nov;10(5):363-74. doi: 10.1016/j.ccr.2006.08.023. PMID: 17097559. Deshpande AJ, Deshpande A, Sinha AU, Chen L, Chang J, Cihan A, Fazio M, Chen CW, Zhu N, Koche R, Dzhekieva L, Ibáñez G, Dias S, Banka D, Krivtsov A, Luo M, Roeder RG, Bradner JE, Bernt KM, Armstrong SA. AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes. Cancer Cell. 2014 Dec 8;26(6):896-908. doi: 10.1016/j.ccell.2014.10.009. Epub 2014 Nov 20. PMID: 25464900; PMCID: PMC4291116. Sinha S, Barbosa K, Cheng K, Leiserson MDM, Jain P, Deshpande A, Wilson DM 3rd, Ryan BM, Luo J, Ronai ZA, Lee JS, Deshpande AJ, Ruppin E. A systematic genome-wide mapping of oncogenic mutation selection during CRISPR-Cas9 genome editing. Nat Commun. 2021 Nov 11;12(1):6512. doi: 10.1038/s41467-021-26788-6. Erratum in: Nat Commun. 2022 May 16;13(1):2828. doi: 10.1038/s41467-022-30475-5. PMID: 34764240; PMCID: PMC8586238.   Related Episodes Targeting COMPASS to Cure Childhood Leukemia (Ali Shilatifard) The Menin-MLL Complex and Small Molecule Inhibitors (Yadira Soto-Feliciano) MLL Proteins in Mixed-Lineage Leukemia (Yali Dou)   Contact Epigenetics Podcast on Mastodon Epigenetics Podcast on Bluesky Dr. Stefan Dillinger on LinkedIn Active Motif on LinkedIn Active Motif on Bluesky Email: podcast@activemotif.com

Dr. John Sweetenham and Dr. Erika Hamilton discuss top abstracts that will be presented at the 2025 ASCO Annual Meeting, including research on tech innovations that could shape the future of oncology. Transcript Dr. John Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham, and I'm delighted to be joined today by Dr. Erika Hamilton, a medical oncologist and director of breast cancer and gynecologic cancer research at the Sarah Cannon Research Institute in Nashville, Tennessee. Dr. Hamilton is also the chair of the 2025 ASCO Annual Meeting Scientific Program, and she's here to tell us about some of the key abstracts, hot topics, and novel approaches in cancer care that will be featured at this year's Annual Meeting. Our full disclosures are available in the transcript of this episode. Dr. Hamilton, it's great to have you on the podcast today, and thanks so much for being here. Dr. Erika Hamilton: Thanks, Dr. Sweetenham. I'm glad to be here. Dr. John Sweetenham: Dr. Hamilton, the Presidential Theme of the Annual Meeting this year is ‘Driving Knowledge to Action: Building a Better Future,' and that's reflected in many of the sessions that will focus on action-oriented guidance to improve care for our patients. And as always, there'll be great presentations on practice-changing abstracts that will change treatment paradigms and transform care. Can you tell us about some of the hot topics this year and what you're particularly excited about? Dr. Erika Hamilton: You're right. Dr. Robin Zon's theme is ‘Driving Knowledge to Action: Building a Better Future,' and you're going to see that theme really interlaced throughout the ASCO program this year. We had a record number of submissions. Over 5,000 abstracts will be published, and there'll be about 3,000 presentations, either in oral format or poster presentations. We have 200 dynamic sessions. Many of the discussants will be highlighting key takeaways and how we can translate action-oriented guidance to better treat our patients to build a better future. Our state-of-the-art science will include a Plenary Session. This will feature presentations as well as discussion of each of the presentations for clinical late-breaking abstracts. We have Clinical Science Symposia that I'm particularly excited about this year. These will feature key abstracts as well as discussions and a foundational talk around the subject. We're covering novel antibody-drug conjugate targets, turning “cold” tumors “hot” to include CAR T, as well as the future of cancer detection. There'll be rapid oral abstracts, case-based panels, and this will also feature interactive audience polling and case discussions. I also want to highlight the community connection opportunities. There will be 13 Communities of Practice that will be meeting on-site during ASCO, and there's also really a plethora of networking opportunities for trainees and early-career professionals, a Women's Networking Center, a patient advocate space, and I'm happy to report there will also be live music out on the terrace this year at ASCO. Dr. John Sweetenham: Well, that's going to be a really great addition. I have to say, I think this is always a special time of year because excitement starts to mount as the meeting gets closer and closer. And once the abstracts are out there, I certainly personally feel that the excitement builds. Talking of abstracts, let's dive into some of the key abstracts for this year's meeting. I'd like to start out by asking you about Abstract 505. This reports on 15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer in the SOFT and TEXT trials. It assesses the benefits of adjuvant exemestane and ovarian function suppression or tamoxifen and ovarian function suppression. So, could you talk us through this and tell us what you think the key takeaways from this abstract are? Dr. Erika Hamilton: Absolutely. This is essentially the SOFT and TEXT trials. They are trials that we've been following for quite some time, evidenced by the 15-year outcome. And I think it really answers two very important questions for us regarding adjuvant endocrine therapy for patients that are facing hormone receptor-positive disease. The benefit of ovarian function suppression for one, and then second, the benefit of exemestane over tamoxifen, which is our SERM [selective estrogen receptor modulator]. So, in terms of the SOFT trial, when we talk about distance recurrence-free interval, which I really think is probably the most meaningful because secondary cancers, et cetera, are not really what we're getting at here. But in terms of distant recurrence-free interval, certainly with tamoxifen, using tamoxifen plus ovarian function suppression adds a little bit. But where we really get additional benefits are by moving to exemestane, an aromatase inhibitor with the ovarian function suppression. So, for example, in SOFT, for distant recurrence-free interval for patients that have received prior chemotherapy, the distance recurrence-free interval was 73.5% with tamoxifen, bumped up just a tiny bit to 73.8% with ovarian function suppression. But when we used both ovarian function suppression and switched to that aromatase inhibitor, we're now talking about 77.6%. It may seem like these are small numbers, but when we talk about an absolute benefit of 4%, these are the type of decisions that we decide whether to offer chemotherapy based on. So, really just optimizing endocrine therapy really can provide additional benefits for these patients. Just briefly, when we turn to TEXT, similarly, when we look at distance recurrence-free interval for our patients that are at highest risk and receive chemotherapy, tamoxifen and ovarian function suppression, 79%; 81% with exemestane and ovarian function suppression. And when we talk about our patients that did not receive chemotherapy, it increased from 91.6% up to 94.6%—very similar that 3% to 4% number. So, I think that this is just very important information when counseling our patients about the decisions that they're going to make for themselves in the adjuvant setting and how much we want to optimize endocrine therapy. Dr. John Sweetenham: Thanks so much for your insight into that. Dr. Erika Hamilton: Yeah, absolutely. So, let's turn to hematologic malignancies. Abstract 6506 reports exciting results on the new agent ziftomenib in relapsed/refractory NPM1-mutant acute myeloid leukemia. This is a phase 1b clinical activity study and safety results. This was the pivotal KOMET-001 study. And my question is, will this new agent fulfill an unmet need in this NPM1 space? Dr. John Sweetenham: Yeah, great question. And I think the answer is almost certainly ‘yes'. So, just as some brief background, NPM1 mutation is known to be a driver of leukemogenesis in around 30% of patients with AML, and it's a poor prognostic factor. And typically, about 50% of these patients will relapse within a year of their first-line therapy, and only around 10% of them will get a subsequent complete remission with salvage therapy. Menin inhibitors, which disrupt the interaction between menin and KMT2A, are known to be active in NPM1-mutated as well as in KMT2A-rearranged AML. And ziftomenib is a selective oral menin inhibitor, which in this study was evaluated at a dose of 600 mg once a day, as you mentioned, a phase 1b/2 study, which is multicenter and presented by Dr. Eunice Wang from Roswell Park. It's a relatively large study of 112 patients who were treated with this standard dose with relatively short median follow-up at this time. The median age was 69 years, and median prior therapies were two, but with a range of one to seven. And I think very importantly, 60% of these patients had previously been treated with venetoclax, and 23% of them had had a prior transplant. Looking at the results overall for this study, the overall response rate was 35%, which is actually quite impressive. Specifically for those patients in the phase 2 part of the study, around 23% achieved a CR [complete remission] or CRh [complete remission with partial hematologic recovery]. What's very interesting in my mind is that the response rates were comparable in venetoclax-naive and venetoclax-exposed patients. And the drug was very well tolerated, with only 3% of patients having to discontinue because of treatment-related adverse events. And I think the authors appropriately conclude that, first of all, the phase 2 primary endpoint in the study was met, and that ziftomenib achieved deep and durable responses in relapsed and refractory NPM1-mutated AML, regardless of prior venetoclax, with good tolerance of the drug. And so, I think putting all of this together, undoubtedly, these data do support the potential use of this agent as monotherapy and as a new option for those patients who have relapsed or refractory NPM1-mutated acute myeloid leukemia. So, let's move on a little bit more now and change the subject and change gears completely and talk about circulating tumor DNA [ctDNA]. This has been a hot topic over a number of years now, and at this year's meeting, there are quite a few impactful studies on the use of ctDNA. We have time to focus on just one of these, and I wanted to get your thoughts on Abstract 4503. This is from the NIAGARA trial, which looks at ctDNA in patients with muscle-invasive bladder cancer who receive perioperative durvalumab. Could you tell us a little bit about this study? Dr. Erika Hamilton: So, this was the phase 3 NIAGARA trial, and this is literally looking for patients with muscle-invasive bladder cancer that are cisplatin-eligible, and the addition of durvalumab to neoadjuvant chemotherapy. So here, this is a planned exploratory analysis of ctDNA and the association with clinical outcomes from NIAGARA. So, this is really the type of study that helps us determine which of our patients are more likely to have a good outcome and which of our patients are more likely not to. There were 1,000 randomized patients in this study, and 462 comprised the biomarker-evaluable population. There were about half in the control arm and half in the durvalumab arm. And overall, the ctDNA-positive rate at baseline was about 57%, or a little over half, and that had decreased to about 22% after neoadjuvant treatment. ctDNA clearance rates from baseline to pre-radical cystectomy was about 41% among those with durvalumab and 31% among those in control. And the non-pCR rate was 97% among patients with pre-cystectomy ctDNA-positive status. So, this really gives us some information about predicting who is going to have better outcomes here. We did see a disease-free survival benefit with perioperative durvalumab, and this was observed in post-cystectomy ctDNA-positive as well as the ctDNA-negative groups. Shifting gears now to GI cancer, Abstract 3506 is a long-term safety and efficacy study of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer. And this is the CodeBreaK-101 study. What are your thoughts on this study? Dr. John Sweetenham: Yeah, thanks. A very interesting study, and this abstract builds upon the phase 3 CodeBreaK-300 trial, which I think has just been published in the Journal of Clinical Oncology. This showed that the combination of sotorasib and panitumumab improved clinical outcomes in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer. The current abstract, as you mentioned, reports the CodeBreaK-101 trial. And this was a phase 1b trial where FOLFIRI therapy was added to sotorasib and panitumumab in previously treated patients with KRAS G12C-mutated metastatic colorectal cancer. The abstract reports the overall and progression-free survival results, as well as some updated safety and response data. So, in this study, patients with this particular mutation who had received at least one prior systemic treatment but were KRAS G12C inhibitor-naive were enrolled into an expansion cohort of the CodeBreaK-101 protocol. And these patients received what apparently now recommended as the standard phase 2 dose of sotorasib of 960 mg daily, plus panitumumab and a standard dose of FOLFIRI. And the primary endpoint of the study was safety, and secondary endpoints included confirmed response, overall response, and progression-free survival, as assessed by the investigator. And by November of last year, 40 patients had been enrolled into this study. Common treatment-related adverse events were cutaneous; some patients developed neutropenia, and stomatitis was fairly widespread. Discontinuation of sotorasib because of adverse events was only seen in 1% of patients, although patients did have to discontinue because of toxicity from some of the other agents in the combination. Looking at the results of this study, the updated objective response rate was 57.5%, and the disease control rate was estimated at 92%, going on 93%, with a median time to response of 1.6 months and a median response duration of 6 months. After a median follow-up of 29.2 months, the median progression-free survival was 8.2 months, and the overall survival 17.9 months. So, the authors have concluded that this combination, including sotorasib, panitumumab, and FOLFIRI, does appear to show quite promising long-term efficacy in pretreated patients with this specific mutation. The ongoing phase 3 study they mentioned, CodeBreaK-301, is aiming to evaluate this combination against the standard of care in the first-line setting for patients with KRAS G12C-mutated colorectal cancer. So, promising results, and we'd be very interested to see how this particular combination performs in the frontline. Dr. Erika Hamilton: Fantastic. Thanks so much for sharing that. Let's shift gears again and really talk about digital technology. I feel that we're all going to have to get much better with this, and really, there are a lot of promises for our patients coming here. There are a lot of abstracts at ASCO that are focusing on innovations in digital technology, including a really interesting psychosocial digital application for caregivers of patients that are undergoing hematopoietic stem cell transplantation. Can you tell us a little bit about this? It's Abstract 11000. Dr. John Sweetenham: Yeah, absolutely. This abstract certainly caught my eye, and I think it's intriguing for a number of reasons, partly because it's app-based, and partly also because it specifically addresses caregiver burden and caregiver needs in the oncology setting, which I think is especially important. And although the context, the clinical context of this study, is hematopoietic stem cell transplantation, I think it has potential applications way beyond that. We all know that caregivers of patients undergoing stem cell transplantation have significant quality-of-life struggles. They are well-documented to have significant psychological and emotional strain before, during, and after stem cell transplantation. And this abstract describes an application called BMT-CARE, which is aimed at improving caregivers' quality of life, caregiver burden, mood symptoms, and coping skills, and so on. So, this was a single-center, randomized trial from MGH [Massachusetts General Hospital] of this app for stem cell transplant caregivers, compared with usual care in those individuals. And the eligible patients, or eligible individuals, were adults caring for patients with heme malignancy undergoing either an autologous or an allogeneic stem cell transplant. Patients were randomly assigned either to use the app or for usual care. And the app itself—and I think it'll be interesting to actually see this at the meeting and visualize it and see how user-friendly and so on it is—but it comprises five modules, which integrate psychoeducation, behavior change, stress management, and they're delivered through a kind of interactive platform of educational games and videos. And then participants were self-reporting at baseline and then 60 days after transplant. So, around 125 patients were enrolled in this study, of around 174 who were initially approached. So, just over 70% uptake from caregivers, which is, I think, relatively high, and evenly distributed between the two randomized arms. And the majority of the participants were spouses. And at 60 days post-stem cell transplant, the intervention participants reported a better quality of life compared with those who received usual care. If you break this down a little bit more, these participants reported lower caregiving burden, lower incidence of depression, fewer PTSD symptoms, and overall better coping skills. So, the authors conclude that this particular app, a digital health intervention, led to pretty substantial improvements in quality of life for these caregivers. So, intriguing. As I said, it'll be particularly interesting to see how this thing looks during the meeting. But if these kind of results can be reproduced, I think this sort of application has potential uses way beyond the stem cell transplant setting. Dr. Erika Hamilton: Yeah, I find that just so fascinating and very needed. I think that the caregiving role is often underestimated in how important that is for the patient and the whole family, and really giving our caregivers more tools in their toolbox certainly is quite helpful. Dr. John Sweetenham: Absolutely. Well, the meeting is getting closer, and as I mentioned earlier, I think anticipation is mounting. And I wanted to say thanks so much to you for chatting with me today about some of the interesting advances in oncology that we're going to see at this year's meeting. There is a great deal more to come. Our listeners can access links to the studies we've discussed today in the transcript of this episode. I'm also looking forward, Dr. Hamilton, to having you back on the podcast after the Annual Meeting to dive into some of the late-breaking abstracts and some of the other key science that's captured the headlines this year. So, thanks once again for joining me today. Dr. Erika Hamilton: Thanks so much for having me. Pleasure. Dr. John Sweetenham: And thank you to our listeners for joining us today. Be sure to catch my “Top Takeaways from ASCO25.” These are short episodes that will drop each day of the meeting at 5:30 p.m. Eastern Time. So, subscribe to the ASCO Daily News Podcast wherever you prefer to listen, and join me for concise analyses of the meeting's key abstracts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   More on today's speakers: Dr. John Sweetenham   Dr. Erika Hamilton @erikahamilton9   Follow ASCO on social media:  @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:     Dr. John Sweetenham:     No relationships to disclose  Dr. Erika Hamilton: Consulting or Advisory Role (Inst): Pfizer, Genentech/Roche, Lilly, Daiichi Sankyo, Mersana, AstraZeneca, Novartis, Ellipses Pharma, Olema Pharmaceuticals, Stemline Therapeutics, Tubulis, Verascity Science, Theratechnologies, Accutar Biotechnology, Entos, Fosun Pharma, Gilead Sciences, Jazz Pharmaceuticals, Medical Pharma Services, Hosun Pharma, Zentalis Pharmaceuticals, Jefferies, Tempus Labs, Arvinas, Circle Pharma, Janssen, Johnson and Johnson   Research Funding (Inst): AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Millenium, TapImmune, Inc., Lilly, Pfizer, Lilly, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Macrogenics, Abbvie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, InventisBio, Deciphera, Sermonix Pharmaceuticals, Zenith Epigentics, Arvinas, Harpoon, Black Diamond, Orinove, Molecular Templates, Seattle Genetics, Compugen, GI Therapeutics, Karyopharm Therapeutics, Dana-Farber Cancer Hospital, Shattuck Labs, PharmaMar, Olema Pharmaceuticals, Immunogen, Plexxikon, Amgen, Akesobio Australia, ADC Therapeutics, AtlasMedx, Aravive, Ellipses Pharma, Incyte, MabSpace Biosciences, ORIC Pharmaceuticals, Pieris Pharmaceuticals, Pieris Pharmaceuticals, Pionyr, Repetoire Immune Medicines, Treadwell Therapeutics, Accutar Biotech, Artios, Bliss Biopharmaceutical, Cascadian Therapeutics, Dantari, Duality Biologics, Elucida Oncology, Infinity Pharmaceuticals, Relay Therapeutics, Tolmar, Torque, BeiGene, Context Therapeutics, K-Group Beta, Kind Pharmaceuticals, Loxo Oncology, Oncothyreon, Orum Therapeutics, Prelude Therapeutics, Profound Bio, Cullinan Oncology, Bristol-Myers Squib, Eisai, Fochon Pharmaceuticals, Gilead Sciences, Inspirna, Myriad Genetics, Silverback Therapeutics, Stemline Therapeutics

We're touching The Laundry down in a single country – to understand how it looks at financial crime and the lessons we can take from it.This episode: a nation where a scam involving tulip sellers can make international news!Our expert host, Marit Rødevand, is joined by Erik Reissenweber, Anti-Money Laundering Specialist at AMLC, to reveal: everything you need to know about financial crime in the Netherlands. The pair discuss: the importance of collaboration to the 'Dutch approach', reporting both unusual and suspicious transactions, and the ING fine which rocked the banking sector. Producer: Matthew Dunne-MilesEditor: Dominic DelargyEngineer: Nicholas Thon____________________________________The Laundry podcast explores the complex world of financial crime, anti-money laundering (AML), compliance, sanctions, and global financial regulation.Hosted by Marit Rødevand, Fredrik Riiser, and Robin Lycka, each episode features in-depth conversations with leading experts from banking, fintech, regulatory bodies, and investigative journalism.Tune in as we dissect headline news, unpack regulatory trends, and examine the real-world consequences of non-compliance — all through a uniquely compliance-focused lens.The Laundry is proudly produced by Strise.Subscribe to our newsletter, Fresh Laundry, here.Get in touch at: laundry@strise.ai Hosted on Acast. See acast.com/privacy for more information.

In this episode of AML Conversations, Joe McNamara, Director of Solutions Marketing at AML RightSource, sits down with Vesna McCreery, a seasoned financial crime compliance expert and Managing Director at AML RightSource, to dissect the alarming rise in global fraud. Together, they explore the historical divergence and recent convergence between fraud prevention and AML functions, the trillion-dollar scale of the fraud problem, and how digitalization, AI-driven deepfakes, and cross-border criminal networks are transforming the landscape. Vesna draws on international comparisons—highlighting Australia's standout success in reducing fraud through real-time public-private partnerships—and shares actionable insights on integrating biometric controls, enhancing data utilization, and reducing false positives in financial institutions. This conversation delivers critical takeaways for professionals navigating the evolving threats in financial crime.

 21st May: Blockchain DXB podcast

See More HERE! In this episode of Fintech Confidential, host Tedd Huff is joined by CI (Confidential Informant), Robert Musiala, co-leader of the Web3 and Digital Assets team at BakerHostetler, to discuss the significant developments in the crypto and fintech space during April 2025. Robert shares his expertise on blockchain law and compliance, providing insights into the evolving regulatory landscape and its impact on the industry.The conversation covers the mainstream adoption of stablecoins, the implications of the Payment Stablecoin Act, and the integration of crypto with traditional financial systems. They also delve into the expansion of programmable money, the shifting regulatory environment, and the growing security threats in the crypto space.Takeaways:1️⃣ Stablecoins are becoming a viable solution for faster and more transparent payments.2️⃣ The Payment Stablecoin Act is prompting companies to adjust their strategies in anticipation of new regulations.3️⃣ Kraken's expansion demonstrates the blending of crypto and traditional finance.4️⃣ Programmable money is enabling automation in financial processes.5️⃣ Security remains a top concern, with sophisticated attacks targeting the crypto infrastructure.Links:Guest:Robert A. Musiala Jr. BakerHostetler Profile: https://www.bakerlaw.com/professionals/robert-a-musiala-jr/LinkedIn: https://www.linkedin.com/in/robert-a-musiala-jr-esq-cfcs-b6534bb/Company:BakerHostetler: https://www.bakerlaw.com/The Blockchain Monitor: https://www.theblockchainmonitor.com/Fintech Confidential:Podcast: https://fintechconfidential.com/listenNotifications: https://fintechconfidential.com/accessLinkedIn: https://www.linkedin.com/company/fintechconfidentialX: https://x.com/FTconfidentialInstagram: https://www.instagram.com/fintechconfidentialFacebook: https://www.facebook.com/fintechconfidentialSupporters:Bitcoin 2025 - Bringing together digital asset leaders in Las Vegas to explore Bitcoin's role in capital markets, featuring speakers like Michael Saylor, Caitlin Long, and Elizabeth Stark - https://fintechconfidential.com/btc25DFNS - Offering Wallets as a Service with military-grade security and enterprise-grade scalability - https://fintechconfidential.com/dfnsSkyflow - Helping FinTechs build secure experiences without managing customer data directly - https://skyflowsecure.comHawk AI - Providing real-time fraud prevention and AML compliance for FinTechs - https://getHawkai.comAbout:Guest: Robert Musiala has been working in the blockchain and digital assets market since 2012 and has led multiple digital asset investigations, including as the court-appointed receiver over cryptocurrency investment funds used in a major fraud. He advises on various regulatory compliance issues involving digital assets and has drafted/negotiated agreements for a wide range of transactions in the fintech, digital assets, Web3, and NFT markets. He is the inventor of two blockchain patents and co-leader of the Web3 and Digital Assets team at BakerHostetler.Host: Tedd Huff is the Founder of Voalyre and Diamond D3, professional services consulting firms focused on global payments and marketing. He is also a video podcast host and executive producer on the Fintech Confidential network. Over the past 24 years, he has contributed to FinTech startups as an Advisory Board Member, Co-Founder, and Chief Experience Officer, providing strategic and tactical direction for global companies, focusing on growth...

Gründer Jacob Wende erzählt im Gespräch mit Host André Bajorat von der Gründung des Fintechs und welche Chancen er dank Künstlicher Intelligenz im Bereich Betrugsprävention sieht.

Rhea Sharma, winner of the Risky Women Write competition, discussed the human costs of offshoring GRC functions. She highlighted the disparity in pay between offshore and onshore employees, noting that offshore employees often face an illusion of progress. Rhea emphasized the need for fair pay, transparency, and inclusion in offshoring practices. She also shared her background, including her work with Women's Lantern, a charity supporting South East Asian women, and her ongoing education. Rhea advocated for decentralized finance and its potential to address global cybersecurity issues, citing regulatory reforms in Australia, Singapore, and India. SHOW NOTES 00:24 Feedback on Rhea's Article 04:36 Career Journey 07:36 Aligning Values with Work 19:46 Challenges of Offshoring and Brain Drain 25:52 Practical Steps for Ethical Offshoring 31:49 Future Innovations and Recommendations Transcript and more GRC content: https://www.riskywomen.org/2025/05/podcast-s8e5-offshoring-grc-functions-the-human-reality/

Listen to ASCO's JCO Oncology Practice, Art of Oncology Practice article, "An Oncologist's Guide to Ensuring Your First Medical Grand Rounds Will Be Your Last” by Dr. David Johnson, who is a clinical oncologist at University of Texas Southwestern Medical School. The article is followed by an interview with Johnson and host Dr. Mikkael Sekeres. Through humor and irony, Johnson critiques how overspecialization and poor presentation practices have eroded what was once internal medicine's premier educational forum. Transcript Narrator: An Oncologist's Guide to Ensuring Your First Medical Grand Rounds Will Be Your Last, by David H. Johnson, MD, MACP, FASCO   Over the past five decades, I have attended hundreds of medical conferences—some insightful and illuminating, others tedious and forgettable. Among these countless gatherings, Medical Grand Rounds (MGRs) has always held a special place. Originally conceived as a forum for discussing complex clinical cases, emerging research, and best practices in patient care, MGRs served as a unifying platform for clinicians across all specialties, along with medical students, residents, and other health care professionals. Expert speakers—whether esteemed faculty or distinguished guests—would discuss challenging cases, using them as a springboard to explore the latest advances in diagnosis and treatment. During my early years as a medical student, resident, and junior faculty member, Grand Rounds consistently attracted large, engaged audiences. However, as medicine became increasingly subspecialized, attendance began to wane. Lectures grew more technically intricate, often straying from broad clinical relevance. The patient-centered discussions that once brought together diverse medical professionals gradually gave way to hyperspecialized presentations. Subspecialists, once eager to share their insights with the wider medical community, increasingly withdrew to their own specialty-specific conferences, further fragmenting the exchange of knowledge across disciplines. As a former Chair of Internal Medicine and a veteran of numerous MGRs, I observed firsthand how these sessions shifted from dynamic educational exchanges to highly specialized, often impenetrable discussions. One of the most striking trends in recent years has been the decline in presentation quality at MGR—even among local and visiting world-renowned experts. While these speakers are often brilliant clinicians and investigators, they can also be remarkably poor lecturers, delivering some of the most uninspiring talks I have encountered. Their presentations are so consistently lackluster that one might suspect an underlying strategy at play—an unspoken method to ensure that they are never invited back. Having observed this pattern repeatedly, I am convinced that these speakers must be adhering to a set of unwritten rules to avoid future MGR presentations. To assist those unfamiliar with this apparent strategy, I have distilled the key principles that, when followed correctly, all but guarantee that a presenter will not be asked to give another MGR lecture—thus sparing them the burden of preparing one in the future. Drawing on my experience as an oncologist, I illustrate these principles using an oncology-based example although I suspect similar rules apply across other subspecialties. It will be up to my colleagues in cardiology, endocrinology, rheumatology, and beyond to identify and document their own versions—tasks for which I claim no expertise. What follows are the seven “Rules for Presenting a Bad Medical Oncology Medical Grand Rounds.” 1.  Microscopic Mayhem: Always begin with an excruciatingly detailed breakdown of the tumor's histology and molecular markers, emphasizing how these have evolved over the years (eg, PAP v prostate-specific antigen)—except, of course, when they have not (eg, estrogen receptor, progesterone receptor, etc). These nuances, while of limited relevance to general internists or most subspecialists (aside from oncologists), are guaranteed to induce eye-glazing boredom and quiet despair among your audience. 2. TNM Torture: Next, cover every nuance of the newest staging system … this is always a real crowd pleaser. For illustrative purposes, show a TNM chart in the smallest possible font. It is particularly helpful if you provide a lengthy review of previous versions of the staging system and painstakingly cover each and every change in the system. Importantly, this activity will allow you to disavow the relevance of all previous literature studies to which you will subsequently refer during the course of your presentation … to wit—“these data are based on the OLD staging system and therefore may not pertain …” This phrase is pure gold—use it often if you can. NB: You will know you have “captured” your audience if you observe audience members “shifting in their seats” … it occurs almost every time … but if you have failed to “move” the audience … by all means, continue reading … there is more! 3. Mechanism of Action Meltdown: Discuss in detail every drug ever used to treat the cancer under discussion; this works best if you also give a detailed description of each drug's mechanism of action (MOA). General internists and subspecialists just LOVE hearing a detailed discussion of the drug's MOA … especially if it is not at all relevant to the objectives of your talk. At this point, if you observe a wave of slack-jawed faces slowly slumping toward their desktops, you will know you are on your way to successfully crushing your audience's collective spirit. Keep going—you are almost there. 4. Dosage Deadlock: One must discuss “dose response” … there is absolutely nothing like a dose response presentation to a group of internists to induce cries of anguish. A wonderful example of how one might weave this into a lecture to generalists or a mixed audience of subspecialists is to discuss details that ONLY an oncologist would care about—such as the need to dose escalate imatinib in GIST patients with exon 9 mutations as compared with those with exon 11 mutations. This is a definite winner! 5. Criteria Catatonia: Do not forget to discuss the newest computed tomography or positron emission tomography criteria for determining response … especially if you plan to discuss an obscure malignancy that even oncologists rarely encounter (eg, esthesioneuroblastoma). Should you plan to discuss a common disease you can ensure ennui only if you will spend extra time discussing RECIST criteria. Now if you do this well, some audience members may begin fashioning their breakfast burritos into projectiles—each one aimed squarely at YOU. Be brave … soldier on! 6. Kaplan-Meier Killer: Make sure to discuss the arcane details of multiple negative phase II and III trials pertaining to the cancer under discussion. It is best to show several inconsequential and hard-to-read Kaplan-Meier plots. To make sure that you do a bad job, divide this portion of your presentation into two sections … one focused on adjuvant treatment; the second part should consist of a long boring soliloquy on the management of metastatic disease. Provide detailed information of little interest even to the most ardent fan of the disease you are discussing. This alone will almost certainly ensure that you will never, ever be asked to give Medicine Grand Rounds again. 7. Lymph Node Lobotomy: For the coup de grâce, be sure to include an exhaustive discussion of the latest surgical techniques, down to the precise number of lymph nodes required for an “adequate dissection.” To be fair, such details can be invaluable in specialized settings like a tumor board, where they send subspecialists into rapturous delight. But in the context of MGR—where the audience spans multiple disciplines—it will almost certainly induce a stultifying torpor. If dullness were an art, this would be its masterpiece—capable of lulling even the most caffeinated minds into a stupor. If you have carefully followed the above set of rules, at this point, some members of the audience should be banging their heads against the nearest hard surface. If you then hear a loud THUD … and you're still standing … you will know you have succeeded in giving the world's worst Medical Grand Rounds!   Final Thoughts I hope that these rules shed light on what makes for a truly dreadful oncology MGR presentation—which, by inverse reasoning, might just serve as a blueprint for an excellent one. At its best, an outstanding lecture defies expectations. One of the most memorable MGRs I have attended, for instance, was on prostaglandin function—not a subject typically associated with edge-of-your-seat suspense. Given by a biochemist and physician from another subspecialty, it could have easily devolved into a labyrinth of enzymatic pathways and chemical structures. Instead, the speaker took a different approach: rather than focusing on biochemical minutiae, he illustrated how prostaglandins influence nearly every major physiologic system—modulating inflammation, regulating cardiovascular function, protecting the gut, aiding reproduction, supporting renal function, and even influencing the nervous system—without a single slide depicting the prostaglandin structure. The result? A room full of clinicians—not biochemists—walked away with a far richer understanding of how prostaglandins affect their daily practice. What is even more remarkable is that the talk's clarity did not just inform—it sparked new collaborations that shaped years of NIH-funded research. Now that was an MGR masterpiece. At its core, effective scientific communication boils down to three deceptively simple principles: understanding your audience, focusing on relevance, and making complex information accessible.2 The best MGRs do not drown the audience in details, but rather illuminate why those details matter. A great lecture is not about showing how much you know, but about ensuring your audience leaves knowing something they didn't before. For those who prefer the structured wisdom of a written guide over the ramblings of a curmudgeon, an excellent review of these principles—complete with a handy checklist—is available.2 But fair warning: if you follow these principles, you may find yourself invited back to present another stellar MGRs. Perish the thought! Dr. Mikkael SekeresHello and welcome to JCO's Cancer Stories: The Art of Oncology, which features essays and personal reflections from authors exploring their experience in the oncology field. I'm your host, Mikkael Sekeres. I'm Professor of Medicine and Chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center, University of Miami.  What a pleasure it is today to be joined by Dr. David Johnson, clinical oncologist at the University of Texas Southwestern Medical School. In this episode, we will be discussing his Art of Oncology Practice article, "An Oncologist's Guide to Ensuring Your First Medical Grand Rounds Will Be Your Last."  Our guest's disclosures will be linked in the transcript.  David, welcome to our podcast and thanks so much for joining us. Dr. David JohnsonGreat to be here, Mikkael. Thanks for inviting me. Dr. Mikkael SekeresI was wondering if we could start with just- give us a sense about you. Can you tell us about yourself? Where are you from? And walk us through your career. Dr. David JohnsonSure. I grew up in a small rural community in Northwest Georgia about 30 miles south of Chattanooga, Tennessee, in the Appalachian Mountains. I met my wife in kindergarten. Dr. Mikkael SekeresOh my. Dr. David JohnsonThere are laws in Georgia. We didn't get married till the third grade. But we dated in high school and got married after college. And so we've literally been with one another my entire life, our entire lives. Dr. Mikkael SekeresMy word. Dr. David JohnsonI went to medical school in Georgia. I did my training in multiple sites, including my oncology training at Vanderbilt, where I completed my training. I spent the next 30 years there, where I had a wonderful career. Got an opportunity to be a Division Chief and a Deputy Director of, and the founder of, a cancer center there. And in 2010, I was recruited to UT Southwestern as the Chairman of Medicine. Not a position I had particularly aspired to, but I was interested in taking on that challenge, and it proved to be quite a challenge for me. I had to relearn internal medicine, and really all the subspecialties of medicine really became quite challenging to me. So my career has spanned sort of the entire spectrum, I suppose, as a clinical investigator, as an administrator, and now as a near end-of-my-career guy who writes ridiculous articles about grand rounds. Dr. Mikkael SekeresNot ridiculous at all. It was terrific. What was that like, having to retool? And this is a theme you cover a little bit in your essay, also, from something that's super specialized. I mean, you have had this storied career with the focus on lung cancer, and then having to expand not only to all of hematology oncology, but all of medicine. Dr. David JohnsonIt was a challenge, but it was also incredibly fun. My first few days in the chair's office, I met with a number of individuals, but perhaps the most important individuals I met with were the incoming chief residents who were, and are, brilliant men and women. And we made a pact. I promised to teach them as much as I could about oncology if they would teach me as much as they could about internal medicine. And so I spent that first year literally trying to relearn medicine. And I had great teachers. Several of those chiefs are now on the faculty here or elsewhere. And that continued on for the next several years. Every group of chief residents imparted their wisdom to me, and I gave them what little bit I could provide back to them in the oncology world. It was a lot of fun. And I have to say, I don't necessarily recommend everybody go into administration. It's not necessarily the most fun thing in the world to do. But the opportunity to deal one-on-one closely with really brilliant men and women like the chief residents was probably the highlight of my time as Chair of Medicine. Dr. Mikkael SekeresThat sounds incredible. I can imagine, just reflecting over the two decades that I've been in hematology oncology and thinking about the changes in how we diagnose and care for people over that time period, I can only imagine what the changes had been in internal medicine since I was last immersed in that, which would be my residency. Dr. David JohnsonWell, I trained in the 70s in internal medicine, and what transpired in the 70s was kind of ‘monkey see, monkey do'. We didn't really have a lot of understanding of pathophysiology except at the most basic level. Things have changed enormously, as you well know, certainly in the field of oncology and hematology, but in all the other fields as well. And so I came in with what I thought was a pretty good foundation of knowledge, and I realized it was completely worthless, what I had learned as an intern and resident. And when I say I had to relearn medicine, I mean, I had to relearn medicine. It was like being an intern. Actually, it was like being a medical student all over again. Dr. Mikkael SekeresOh, wow. Dr. David JohnsonSo it's quite challenging.  Dr. Mikkael SekeresWell, and it's just so interesting. You're so deliberate in your writing and thinking through something like grand rounds. It's not a surprise, David, that you were also deliberate in how you were going to approach relearning medicine. So I wonder if we could pivot to talking about grand rounds, because part of being a Chair of Medicine, of course, is having Department of Medicine grand rounds. And whether those are in a cancer center or a department of medicine, it's an honor to be invited to give a grand rounds talk. How do you think grand rounds have changed over the past few decades? Can you give an example of what grand rounds looked like in the 1990s compared to what they look like now? Dr. David JohnsonWell, I should all go back to the 70s and and talk about grand rounds in the 70s. And I referenced an article in my essay written by Dr. Ingelfinger, who many people remember Dr. Ingelfinger as the Ingelfinger Rule, which the New England Journal used to apply. You couldn't publish in the New England Journal if you had published or publicly presented your data prior to its presentation in the New England Journal. Anyway, Dr. Ingelfinger wrote an article which, as I say, I referenced in my essay, about the graying of grand rounds, when he talked about what grand rounds used to be like. It was a very almost sacred event where patients were presented, and then experts in the field would discuss the case and impart to the audience their wisdom and knowledge garnered over years of caring for patients with that particular problem, might- a disease like AML, or lung cancer, or adrenal insufficiency, and talk about it not just from a pathophysiologic standpoint, but from a clinician standpoint. How do these patients present? What do you do? How do you go about diagnosing and what can you do to take care of those kinds of patients? It was very patient-centric. And often times the patient, him or herself, was presented at the grand rounds. And then experts sitting in the front row would often query the speaker and put him or her under a lot of stress to answer very specific questions about the case or about the disease itself.  Over time, that evolved, and some would say devolved, but evolved into more specialized and nuanced presentations, generally without a patient present, or maybe even not even referred to, but very specifically about the molecular biology of disease, which is marvelous and wonderful to talk about, but not necessarily in a grand round setting where you've got cardiologists sitting next to endocrinologists, seated next to nephrologists, seated next to primary care physicians and, you know, an MS1 and an MS2 and et cetera. So it was very evident to me that what I had witnessed in my early years in medicine had really become more and more subspecialized. As a result, grand rounds, which used to be packed and standing room only, became echo chambers. It was like a C-SPAN presentation, you know, where local representative got up and gave a talk and the chambers were completely empty. And so we had to go to do things like force people to attend grand rounds like a Soviet Union-style rally or something, you know. You have to pay them to go. But it was really that observation that got me to thinking about it.  And by the way, I love oncology and I'm, I think there's so much exciting progress that's being made that I want the presentations to be exciting to everybody, not just to the oncologist or the hematologist, for example. And what I was witnessing was kind of a formula that, almost like a pancake formula, that everybody followed the same rules. You know, “This disease is the third most common cancer and it presents in this way and that way.” And it was very, very formulaic. It wasn't energizing and exciting as it had been when we were discussing individual patients. So, you know, it just is what it is. I mean, progress is progress and you can't stop it. And I'm not trying to make America great again, you know, by going back to the 70s, but I do think sometimes we overthink what medical grand rounds ought to be as compared to a presentation at ASH or ASCO where you're talking to subspecialists who understand the nuances and you don't have to explain the abbreviations, you know, that type of thing. Dr. Mikkael SekeresSo I wonder, you talk about the echo chamber of the grand rounds nowadays, right? It's not as well attended. It used to be a packed event, and it used to be almost a who's who of, of who's in the department. You'd see some very famous people who would attend every grand rounds and some up-and-comers, and it was a chance for the chief residents to shine as well. How do you think COVID and the use of Zoom has changed the personality and energy of grand rounds? Is it better because, frankly, more people attend—they just attend virtually. Last time I attended, I mean, I attend our Department of Medicine grand rounds weekly, and I'll often see 150, 200 people on the Zoom. Or is it worse because the interaction's limited? Dr. David JohnsonYeah, I don't want to be one of those old curmudgeons that says, you know, the way it used to be is always better. But there's no question that the convenience of Zoom or similar media, virtual events, is remarkable. I do like being able to sit in my office where I am right now and watch a conference across campus that I don't have to walk 30 minutes to get to. I like that, although I need the exercise. But at the same time, I think one of the most important aspects of coming together is lost with virtual meetings, and that's the casual conversation that takes place. I mentioned in my essay an example of the grand rounds that I attended given by someone in a different specialty who was both a physician and a PhD in biochemistry, and he was talking about prostaglandin metabolism. And talk about a yawner of a title; you almost have to prop your eyelids open with toothpicks. But it turned out to be one of the most fascinating, engaging conversations I've ever encountered. And moreover, it completely opened my eyes to an area of research that I had not been exposed to at all. And it became immediately obvious to me that it was relevant to the area of my interest, which was lung cancer. This individual happened to be just studying colon cancer. He's not an oncologist, but he was studying colon cancer. But it was really interesting what he was talking about. And he made it very relevant to every subspecialist and generalist in the audience because he talked about how prostaglandin has made a difference in various aspects of human physiology.  The other grand rounds which always sticks in my mind was presented by a long standing program director at my former institution of Vanderbilt. He's passed away many years ago, but he gave a fascinating grand rounds where he presented the case of a homeless person. I can't remember the title of his grand rounds exactly, but I think it was “Care of the Homeless” or something like that. So again, not something that necessarily had people rushing to the audience. What he did is he presented this case as a mysterious case, you know, “what is it?” And he slowly built up the presentation of this individual who repeatedly came to the emergency department for various and sundry complaints. And to make a long story short, he presented a case that turned out to be lead poisoning. Everybody was on the edge of their seat trying to figure out what it was. And he was challenging members of the audience and senior members of the audience, including the Cair, and saying, “What do you think?” And it turned out that the patient became intoxicated not by eating paint chips or drinking lead infused liquids. He was burning car batteries to stay alive and inhaling lead fumes, which itself was fascinating, you know, so it was a fabulous grand rounds. And I mean, everybody learned something about the disease that they might otherwise have ignored, you know, if it'd been a title “Lead Poisoning”, I'm not sure a lot of people would have shown up. Dr. Mikkael Sekeres That story, David, reminds me of Tracy Kidder, who's a master of the nonfiction narrative, will choose a subject and kind of just go into great depth about it, and that subject could be a person. And he wrote a book called Rough Sleepers about Jim O'Connell - and Jim O'Connell was one of my attendings when I did my residency at Mass General - and about his life and what he learned about the homeless. And it's this same kind of engaging, “Wow, I never thought about that.” And it takes you in a different direction.  And you know, in your essay, you make a really interesting comment. You reflect that subspecialists, once eager to share their insight with the wider medical community, increasingly withdraw to their own specialty specific conferences, further fragmenting the exchange of knowledge across disciplines. How do you think this affects their ability to gain new insights into their research when they hear from a broader audience and get questions that they usually don't face, as opposed to being sucked into the groupthink of other subspecialists who are similarly isolated? Dr. David Johnson That's one of the reasons I chose to illustrate that prostaglandin presentation, because again, that was not something that I specifically knew much about. And as I said, I went to the grand rounds more out of a sense of obligation than a sense of engagement. Moreover, our Chair at that institution forced us to go, so I was there, not by choice, but I'm so glad I was, because like you say, I got insight into an area that I had not really thought about and that cross pollination and fertilization is really a critical aspect. I think that you can gain at a broad conference like Medical Grand Rounds as opposed to a niche conference where you're talking about APL. You know, everybody's an APL expert, but they never thought about diabetes and how that might impact on their research. So it's not like there's an ‘aha' moment at every Grand Rounds, but I do think that those kinds of broad based audiences can sometimes bring a different perspective that even the speaker, him or herself had not thought of. Dr. Mikkael SekeresI think that's a great place to end and to thank David Johnson, who's a clinical oncologist at the University of Texas Southwestern Medical School and just penned the essay in JCO Art of Oncology Practice entitled "An Oncologist's Guide to Ensuring Your First Medical Grand Rounds Will Be Your Last."  Until next time, thank you for listening to JCO's Cancer Stories: The Art of Oncology. Don't forget to give us a rating or review, and be sure to subscribe so you never miss an episode. You can find all of ASCO's shows at asco.org/podcasts.  David, once again, I want to thank you for joining me today. Dr. David JohnsonThank you very much for having me. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.    Show notes: Like, share and subscribe so you never miss an episode and leave a rating or review.  Guest Bio: Dr David Johnson is a clinical oncologist at the University of Texas Southwestern Medical School.

This week, John and Elliot discuss a large fentanyl bust at the southern border, a fraud case, and an AML case in Charlotte, remarks by the AMLA Chairman about the organization's top three priorities, activity at the House Financial Services Committee about cryptocurrency, a paper from the Basel Institute for Governance on the importance of asset recovery in the current environment, and other items impacting the financial crime prevention community.

In this week's episode, we'll learn more about how measurable residual disease might help guide decisions about post-transplant gilteritinib maintenance in FLT3-ITD acute myeloid leukemia, or AML; how stemness contributes to chemotherapy resistance in AML; and effects of babesiosis on red blood cells from individuals with sickle cell disease, sickle cell trait, and wild-type hemoglobin. Featured Articles:Measurable residual disease and post-transplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML GATA2 links stemness to chemotherapy resistance in acute myeloid leukemia Babesiosis and Sickle Red Blood Cells: Loss of Deformability, Heightened Osmotic fragility and Hyper-vesiculation 

In this episode of Hema Now, Diu Nguyen joins Jonathan Sackier to discuss breakthroughs in acute myeloid leukaemia (AML) research. From RNA-binding proteins to the future of stem cell-targeted therapies, Nguyen shares the translational goals of her lab and what's on the horizon in AML diagnosis and treatment.    Timestamps:  01:20 – Quickfire Insights  03:32 – AML Breakthroughs  04:47 – Leukaemia Surprise  06:42 – Alternate Pathways  07:54 – RNA Differences  12:08 – Diagnostics Future  14:03 – RBMX Spotlight  20:21 – Targeted Therapies  27:07 – Treatment Barriers  31:32 – Three Wishes 

Ever wonder why fraud keeps getting smarter—and harder to stop? In this episode, recorded live at CSI's CX25 conference, Adwait Joshi—CEO and founder of DataSeers—pulls back the curtain on today's toughest fraud and AML headaches.From missing data to misunderstood intent, he breaks down why traditional systems are falling short and what needs to change. If you're in fintech, banking, or just curious about outsmarting financial crime, this episode delivers the real talk and actionable insights you can't afford to miss.Thanks for listening! Feel free to submit questions on X or LinkedIn using #BankingonCommunityPod and give us a follow! LinkedIn X Facebook YouTube

Watch The X22 Report On Video No videos found Click On Picture To See Larger Picture The [DS]/[CB] green agenda is falling apart, everything they said the opposite is happening. Another solar company goes belly up. China is trying to skirt the tariffs, this will fail. The tariffs are working, companies are moving back. Trump messages that we are in a transition and soon the people will see the gold. The [DS] is going down the path that trump sent. They are now exposing their infiltration and people can now see the entrenched enemy. Trump and the patriots are playing the game and it had to be this way to show the people the criminal syndicate. Trump has removed the three sides of the triangle and now the old guard is threatened.   (function(w,d,s,i){w.ldAdInit=w.ldAdInit||[];w.ldAdInit.push({slot:13499335648425062,size:[0, 0],id:"ld-7164-1323"});if(!d.getElementById(i)){var j=d.createElement(s),p=d.getElementsByTagName(s)[0];j.async=true;j.src="//cdn2.customads.co/_js/ajs.js";j.id=i;p.parentNode.insertBefore(j,p);}})(window,document,"script","ld-ajs"); Economy https://twitter.com/KanekoaTheGreat/status/1918915519245381969  approximately 108 gigatons per year. https://twitter.com/TheCalvinCooli1/status/1918390219939934430 https://twitter.com/Rickster_75/status/1918331034493698275 TAKE A LISTEN   European Union To Ban Anonymous Crypto & Privacy Tokens By 2027   The European Union is set to impose sweeping Anti-Money Laundering (AML) rules that will ban privacy-preserving tokens and anonymous cryptocurrency accounts from 2027. Under the new Anti-Money Laundering Regulation (AMLR), credit institutions, financial institutions and crypto asset service providers (CASPs) will be prohibited from maintaining anonymous accounts or handling privacy-preserving cryptocurrencies, such as Monero and Zcash. “Article 79 of the AMLR establishes strict prohibitions on anonymous accounts [...]. Credit institutions, financial institutions, and crypto-asset service providers are prohibited from maintaining anonymous accounts,” according to the AML Handbook, published by European Crypto Initiative (EUCI).   The regulation is part of a broader AML framework that includes bank and payment accounts, passbooks and safe-deposit boxes, “crypto-asset accounts allowing anonymisation of transactions,” and “accounts using anonymity-enhancing coins.” Source: zerohedge.com https://twitter.com/KobeissiLetter/status/1919013699873821077   see a CEO with such a historic run again? https://twitter.com/KanekoaTheGreat/status/1918490939531657501  in homelessness. And they still called it "the best economy ever." China Reroutes Targeted Goods to Friendly North American Partner to Avoid Tariffs As if on cue, a short article from the Chamber of Shipping notes that cargo from China is being rerouted to avoid tariffs. The destination of the cargo is,   CANADA! USCoS –  experts caution that prolonged storage costs—estimated at $1,750 per container per week—and limited warehouse capacity could force sellers to offload discounted goods into the Canadian market, potentially disrupting domestic manufacturing. Others warn the strategy is risky and unsustainable, especially if the trade conflict drags into next year's U.S.-Mexico-Canada Agreement negotiations. (link) This will not end well…. … For Canada. Source: theconservativetreehouse.com When Americans' clothes were made in America U.S. Trade Representative posts shocking chart showing percentage of onshore manufacturing The post reads: "Reviving apparel production in America is not a pipe dream. It was not that long ago we were manufacturing 56% of U.S. apparel in America. 'Made in America' is an economic and national security priority of this administration." "@POTUS' trade actions are ushering in a reshoring renaissance as companies pledge billions of dollars to e...

Oscilar CEO Neha Narkhede discusses AI for risk management, focusing on fraud & financial crime detection. Learn how AI breaks data silos & improves security.

Nasdaq Verafin's EVP and Head of Financial Crime Technology, Stephanie Champion, discusses their 2024 Global Crime Report, highlighting the key concerns of AML professionals and how to approach the need for action.

Matt and Nic are back with another week of news and deals. In this episode: We recap Nic's article on why Signature collapsed Crypto exchange OKX announced their plans to expand to the US Kraken announced that US equities are now supported on the exchange MANTRA, a layer 1 network focused on RWAs, saw the price of its native token crash 90% in a matter of hours Global Payments agreed to acquire Worldpay, a payments processor, for $24 billion from FIS and private equity firm GTCR The US Department of Homeland Security has launched a probe into Anchorage, the digital asset custodian, related to the company's AML polices Jerome Powell reiterates his support for stablecoin legislation Strategy (and others) buy more Bitcoin Content mentioned in this episode: Galaxy Digital,  The State of Crypto Lending Nic Carter in Piratewires, Signature Didn't Have to Die, Either